Do you want to read an article? Please log in or register.
Reductions in insulin resistance are mediated primarily via weight loss in subjects with type 2 diabetes on semaglutide
Type 2 Diabetes
Related content
COMMENTED
Diabetes - GeneralType 2 Diabetes
Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in SUSTAIN 1-5 trials
Diabetes Obes Metab.
Ahrén B, Atkin SL, Charpentier G, Warren ML, Wilding JP, Birch S, Holst AG, Leiter LA
doi: 10.1111/dom.13353.
Type 2 Diabetes
Weight loss in patients with type 2 diabetes (T2D) mellitus receiving once-weekly dulaglutide plus insulin lispro or insulin glargine plus insulin lispro: An AWARD-4 post-hoc analysis across baseline body mass index subgroups
Diabetes Obes Metab.
Fuechtenbusch M, Aberle J, Heitmann E, Nicolay C, Jung H
doi: 10.1111/dom.
Diabetes - GeneralType 2 DiabetesGlycemic Control
Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial
Lancet Diabetes Endocrinol.
Aroda VR, Bain SC, Cariou B, Piletič M, Rose L, Axelsen M, Rowe E, DeVries JH
doi: 10.1016/S2213-8587(17)
COMMENTED
Diabetes - General
Medicines for Treatment Intensification in Type 2 Diabetes and Type of Insulin in Type 1 and Type 2 Diabetes in Low-Resource Settings: Synopsis of the World Health Organization Guidelines on Second- and Third-Line Medicines and Type of Insulin for the Control of Blood Glucose Levels in Nonpregnant Adults With Diabetes Mellitus
Ann Intern Med.
Roglic G, Norris SL
doi: 10.7326/M18-1149.
Diabetes - GeneralType 2 Diabetes
Targeting weight loss interventions to reduce cardiovascular complications of type 2 diabetes: a machine learning-based post-hoc analysis of heterogeneous treatment effects in the Look AHEAD trial
Lancet Diabetes Endocrinol.
Baum A, Scarpa J, Bruzelius E, Tamler R, Basu S, Faghmous J
doi: 10.1016/
COMMENTED
Diabetes - GeneralType 2 DiabetesObesity and Bariatric Surgery
Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-Term Glycemic Response to DPP-4 Inhibitor Therapy
Diabetes Care.
Dennis JM, Shields BM, Hill AV, Knight BA, McDonald TJ, Rodgers LR, Weedon MN, Henley WE, Sattar N, Holman RR, Pearson ER, Hattersley AT, Jones AG; MASTERMIND consortium
doi: 10.2337/dc17-1827.
COMMENTED
Type 2 DiabetesGlycemic Control
Human Regular U-500 Insulin via Continuous Subcutaneous Insulin Infusion vs. Multiple Daily Injections in Adults with Type 2 Diabetes: the VIVID Study
★ 0
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Diabetes Obes Metab.
Grunberger G, Bhargava A, Ly T, Zisser H, Ilag LL, Malone J, Fan L, Zhang S, Johnson J
doi: 10.1111/dom.13947.
COMMENTED
Diabetes - GeneralType 2 DiabetesGlycemic Control
Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial
Diabetes Care.
Ahmann AJ, Capehorn M, Charpentier G, Dotta F, Henkel E, Lingvay I, Holst AG, Annett MP, Aroda VR
doi: 10.2337/dc17-0417.
Diabetes - GeneralType 2 DiabetesGlycemic Control
Complex Assessment of Metabolic Effectiveness of Insulin Pump Therapy in Patients with Type 2 Diabetes Beyond HbA1c Reduction
Diabetes Technol Ther.
Chlup R, Runzis S, Castaneda J, Lee SW, Nguyen X, Cohen O
doi: 10.1089/dia.2017.0283.